Welcome to Paid Research Studies


Browse Locations ... United States» ... Wyoming» ... Cheyenne





  • Conditions:   Ductal Breast Carcinoma;   Invasive Breast Carcinoma;   Lobular Breast Carcinoma;   Medullary Breast Carcinoma;   Stage II Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Tubular Breast Carcinoma
    Interventions:   Radiation: Radiation Therapy;   Other: Questionnaire Administration;   Other: Quality-of-Life Assessment;   Other: Laboratory Biomarker Analysis;   Radiation: Hypofractionated Radiation Therapy
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Chemotherapy-induced Nausea and Vomiting
    Interventions:   Drug: fosnetupitant/ palonosetron;   Drug: netupitant/palonosetron;   Drug: dexamethasone
    Sponsors:   Helsinn Healthcare SA;   George Clinical Pty Ltd;   PSI CRO AG
    Recruiting

  • Conditions:   Breast Carcinoma;   Cervical Carcinoma;   Ovarian Carcinoma;   Postmenopausal;   Uterine Corpus Cancer;   Vaginal Carcinoma;   Vulvar Carcinoma
    Interventions:   Drug: Bupropion Hydrochloride;   Other: Placebo
    Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Implantable Defibrillator User
    Intervention:  
    Sponsor:   Biotronik, Inc.
    Recruiting

  • Conditions:   Stage III Cutaneous Melanoma AJCC v7;   Stage IIIA Cutaneous Melanoma AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7
    Interventions:   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Colorectal Adenocarcinoma;   Mismatch Repair Deficiency;   Stage IV Colorectal Cancer AJCC v7;   Stage IVA Colorectal Cancer AJCC v7;   Stage IVB Colorectal Cancer AJCC v7
    Interventions:   Drug: Atezolizumab;   Biological: Bevacizumab;   Drug: Fluorouracil;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Node Positive HER2 Negative Breast Cancer
    Interventions:   Other: Placebo;   Drug: Aspirin
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   United States Department of Defense;   Bayer
    Recruiting

  • Conditions:   Colon Adenocarcinoma;   DNA Repair Disorder;   Lynch Syndrome;   Stage III Colon Cancer AJCC v7;   Stage IIIA Colon Cancer AJCC v7;   Stage IIIB Colon Cancer AJCC v7;   Stage IIIC Colon Cancer AJCC v7
    Interventions:   Drug: Atezolizumab;   Drug: Fluorouracil;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acinar Cell Carcinoma;   Adenoid Cystic Carcinoma;   Adrenal Cortex Carcinoma;   Adrenal Gland Pheochromocytoma;   Anal Canal Neuroendocrine Carcinoma;   Anal Canal Undifferentiated Carcinoma;   Appendix Mucinous Adenocarcinoma;   Bartholin Gland Transitional Cell Carcinoma;   Bladder Adenocarcinoma;   Cervical Adenocarcinoma;   Cholangiocarcinoma;   Chordoma;   Colorectal Squamous Cell Carcinoma;   Desmoid-Type Fibromatosis;   Endometrial Transitional Cell Carcinoma;   Endometrioid Adenocarcinoma;   Esophageal Neuroendocrine Carcinoma;   Esophageal Undifferentiated Carcinoma;   Extrahepatic Bile Duct Carcinoma;   Fallopian Tube Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fibromyxoid Tumor;   Gastric Neuroendocrine Carcinoma;   Gastric Squamous Cell Carcinoma;   Gastrointestinal Stromal Tumor;   Giant Cell Carcinoma;   Intestinal Neuroendocrine Carcinoma;   Intrahepatic Cholangiocarcinoma;   Lung Carcinoid Tumor;   Lung Sarcomatoid Carcinoma;   Major Salivary Gland Carcinoma;   Malignant Odontogenic Neoplasm;   Malignant Peripheral Nerve Sheath Tumor;   Malignant Testicular Sex Cord-Stromal Tumor;   Metaplastic Breast Carcinoma;   Metastatic Malignant Neoplasm of Unknown Primary Origin;   Minimally Invasive Lung Adenocarcinoma;   Mixed Mesodermal (Mullerian) Tumor;   Mucinous Adenocarcinoma;   Mucinous Cystadenocarcinoma;   Nasal Cavity Adenocarcinoma;   Nasal Cavity Carcinoma;   Nasopharyngeal Carcinoma;   Nasopharyngeal Papillary Adenocarcinoma;   Nasopharyngeal Undifferentiated Carcinoma;   Oral Cavity Carcinoma;   Oropharyngeal Undifferentiated Carcinoma;   Ovarian Adenocarcinoma;   Ovarian Germ Cell Tumor;   Ovarian Mucinous Adenocarcinoma;   Ovarian Squamous Cell Carcinoma;   Ovarian Transitional Cell Carcinoma;   Pancreatic Acinar Cell Carcinoma;   Pancreatic Neuroendocrine Carcinoma;   Paraganglioma;   Paranasal Sinus Adenocarcinoma;   Paranasal Sinus Carcinoma;   Parathyroid Gland Carcinoma;   Pituitary Gland Carcinoma;   Placental Choriocarcinoma;   Placental-Site Gestational Trophoblastic Tumor;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Pseudomyxoma Peritonei;   Rare Disorder;   Scrotal Squamous Cell Carcinoma;   Seminal Vesicle Adenocarcinoma;   Seminoma;   Serous Cystadenocarcinoma;   Small Intestinal Adenocarcinoma;   Small Intestinal Squamous Cell Carcinoma;   Spindle Cell Neoplasm;   Squamous Cell Carcinoma of the Penis;   Teratoma With Malignant Transformation;   Testicular Non-Seminomatous Germ Cell Tumor;   Thyroid Gland Carcinoma;   Tracheal Carcinoma;   Transitional Cell Carcinoma;   Undifferentiated Gastric Carcinoma;   Ureter Adenocarcinoma;   Ureter Squamous Cell Carcinoma;   Urethral Adenocarcinoma;   Urethral Squamous Cell Carcinoma;   Vaginal Adenocarcinoma;   Vaginal Squamous Cell Carcinoma, Not Otherwise Specified;   Vulvar Carcinoma
    Interventions:   Procedure: Biospecimen Collection;   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Breast Carcinoma
    Interventions:   Other: Health Education Program;   Other: Weight Loss Intervention
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Division of Cancer Control;   NIH Biomarker, Imaging and Quality of Life Studies Funding Program (BIQSFP)
    Recruiting

  • Conditions:   Acute Myeloid Leukemia (AML) With;   FLT3 Mutation, Internal Tandem Duplication (ITD) or Tyrosine Kinase Domain (TKD)
    Intervention:   Drug: Midostaurin
    Sponsor:   Novartis Pharmaceuticals
    Available

  • Conditions:   Breast Carcinoma Metastatic in the Brain;   Deleterious BRCA1 Gene Mutation;   Deleterious BRCA2 Gene Mutation;   Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Recurrent Breast Carcinoma;   Stage IV Breast Cancer AJCC v6 and v7;   Triple-Negative Breast Carcinoma
    Interventions:   Drug: Cisplatin;   Other: Laboratory Biomarker Analysis;   Other: Placebo;   Drug: Veliparib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Dedifferentiated Liposarcoma;   Gastrointestinal Stromal Tumor;   Metastatic Liposarcoma;   Metastatic Undifferentiated Pleomorphic Sarcoma;   Pleomorphic Liposarcoma;   Stage III Bone Sarcoma AJCC v7;   Stage III Soft Tissue Sarcoma AJCC v7;   Stage IV Bone Sarcoma AJCC v7;   Stage IV Soft Tissue Sarcoma AJCC v7;   Stage IVA Bone Sarcoma AJCC v7;   Stage IVB Bone Sarcoma AJCC v7;   Unresectable Liposarcoma
    Interventions:   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Advanced Malignant Solid Neoplasm;   Bladder Carcinoma;   Breast Carcinoma;   Cervical Carcinoma;   Colon Carcinoma;   Colorectal Carcinoma;   Endometrial Carcinoma;   Esophageal Carcinoma;   Gastric Carcinoma;   Glioma;   Head and Neck Carcinoma;   Kidney Carcinoma;   Liver and Intrahepatic Bile Duct Carcinoma;   Lung Carcinoma;   Lymphoma;   Malignant Uterine Neoplasm;   Melanoma;   Ovarian Carcinoma;   Pancreatic Carcinoma;   Plasma Cell Myeloma;   Prostate Carcinoma;   Rectal Carcinoma;   Recurrent Bladder Carcinoma;   Recurrent Breast Carcinoma;   Recurrent Cervical Carcinoma;   Recurrent Colon Carcinoma;   Recurrent Colorectal Carcinoma;   Recurrent Esophageal Carcinoma;   Recurrent Gastric Carcinoma;   Recurrent Glioma;   Recurrent Head and Neck Carcinoma;   Recurrent Liver Carcinoma;   Recurrent Lung Carcinoma;   Recurrent Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Melanoma;   Recurrent Ovarian Carcinoma;   Recurrent Pancreatic Carcinoma;   Recurrent Plasma Cell Myeloma;   Recurrent Prostate Carcinoma;   Recurrent Rectal Carcinoma;   Recurrent Skin Carcinoma;   Recurrent Thyroid Gland Carcinoma;   Recurrent Uterine Corpus Carcinoma;   Refractory Lymphoma;   Refractory Malignant Solid Neoplasm;   Refractory Plasma Cell Myeloma;   Skin Carcinoma;   Thyroid Gland Carcinoma;   Uterine Corpus Cancer
    Interventions:   Drug: Adavosertib;   Drug: Afatinib;   Drug: Binimetinib;   Drug: Capivasertib;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Dabrafenib;   Drug: Dasatinib;   Drug: Defactinib;   Drug: FGFR Inhibitor AZD4547;   Other: Laboratory Biomarker Analysis;   Drug: Larotrectinib;   Biological: Nivolumab;   Drug: Osimertinib;   Drug: Palbociclib;   Biological: Pertuzumab;   Drug: PI3K-beta Inhibitor GSK2636771;   Drug: Sapanisertib;   Drug: Sunitinib Malate;   Drug: Taselisib;   Drug: Trametinib;   Biological: Trastuzumab;   Biological: Trastuzumab Emtansine;   Drug: Vismodegib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Diffuse Large B-Cell Lymphoma Activated B-Cell Type;   Diffuse Large B-Cell Lymphoma, Not Otherwise Specified;   High Grade B-Cell Lymphoma, Not Otherwise Specified;   Recurrent Burkitt Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Refractory Burkitt Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma
    Interventions:   Procedure: Autologous Bone Marrow Transplantation;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Etoposide;   Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Other: Pharmacogenomic Study;   Other: Placebo
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   BRAF V600E Mutation Present;   BRAF V600K Mutation Present;   Recurrent Melanoma;   Stage III Cutaneous Melanoma AJCC v7;   Stage IIIA Cutaneous Melanoma AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7
    Interventions:   Drug: Dabrafenib;   Other: Laboratory Biomarker Analysis;   Drug: Trametinib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   ALK Gene Rearrangement;   EGFR Exon 19 Deletion Mutation;   EGFR NP_005219.2:p.L858R;   Stage IB Non-Small Cell Lung Carcinoma AJCC v7;   Stage II Non-Small Cell Lung Cancer AJCC v7;   Stage IIA Non-Small Cell Lung Carcinoma AJCC v7;   Stage IIB Non-Small Cell Lung Carcinoma AJCC v7;   Stage IIIA Non-Small Cell Lung Cancer AJCC v7
    Interventions:   Other: Clinical Observation;   Drug: Erlotinib Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Placebo
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Estrogen Receptor Positive;   HER2/Neu Negative;   Male Breast Carcinoma;   Progesterone Receptor Positive;   Recurrent Breast Carcinoma;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Stage IV Breast Cancer AJCC v6 and v7
    Interventions:   Drug: Entinostat;   Drug: Exemestane;   Drug: Goserelin Acetate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Other: Placebo;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Invasive Ductal Breast Carcinoma;   Invasive Lobular Breast Carcinoma;   Recurrent Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
    Interventions:   Drug: fulvestrant;   Drug: anastrozole
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Stage II Breast Cancer;   Stage IIIA Breast Cancer
    Interventions:   Procedure: Axillary Lymph Node Dissection (ALND);   Radiation: Nodal Radiation Therapy;   Radiation: Axillary Radiation Therapy
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Colorectal Cancer
    Interventions:   Drug: FOLFOX (chemotherapy);   Other: 5 FUCMT (chemoradiation);   Procedure: surgery;   Procedure: magnetic resonance imaging or endorectal ultrasound
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Lung Cancer
    Interventions:   Radiation: Standard Radiation Dose Therapy;   Drug: cisplatin;   Drug: etoposide;   Radiation: High Radiation Dose Therapy;   Drug: carboplatin
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Recruiting